March's focus on colorectal cancer awareness sheds light on a critical aspect of healthcare, especially in the U.S., where it ranks as the third most prevalent cancer. While early detection is widely acknowledged as a cornerstone of effective treatment, the genetic underpinnings of this disease often remain under the radar. Dr. Daniel Sussman, a gastroenterologist at Sylvester, is leading the charge in identifying high-risk individuals and offering personalized prevention plans. This proactive approach is a game-changer, especially for those with a genetic predisposition.
In the realm of colorectal cancer research, Dr. Kevin Van der Jeught's work stands out. His $72,000 Stanley J. Glaser Foundation Award-winning project aims to enhance the body's immune response to anti-PD-1 checkpoint inhibitors. This innovative mRNA-based immunotherapy strategy has the potential to expand the reach of immunotherapy, offering hope to a broader spectrum of patients. The project's progression towards an early-phase clinical trial at Sylvester is a testament to the growing interest in mRNA technologies for cancer treatment.
Breast cancer treatment, while life-saving, can take a toll on patients' physical and emotional well-being. However, a recent Sylvester-led study published in The Lancet Healthy Longevity offers a glimmer of hope. The study highlights the transformative impact of exercise during chemotherapy. Lead author LaShae D. Rolle emphasizes the importance of quality of life during treatment, not just as an afterthought. The findings suggest that exercise can be a powerful tool in rebuilding strength and improving mood and energy levels, offering a much-needed boost to patients' overall well-being.
In the field of prostate cancer research, a Sylvester study has uncovered valuable insights. By tracking metastatic prostate cancer's evolution through serial liquid biopsies, researchers identified consistent androgen receptor (AR) alterations linked to poorer outcomes across therapies. These findings challenge the notion of a one-size-fits-all genomic test at diagnosis, advocating for real-time molecular testing to guide personalized care. This approach has the potential to revolutionize the management of advanced prostate cancer.
Pancreatic cancer, often considered a silent killer, is the focus of Dr. Jashodeep Datta's research. His work, supported by a Stanley J. Glaser Foundation Research Award, aims to decode immune-driven treatment resistance and develop more precise therapies. By blocking the interleukin-1 (IL-1) inflammatory pathway, Dr. Datta's team hopes to weaken the tumor's ability to manipulate the body's immune response. This innovative approach has the potential to improve outcomes for patients eligible for surgery, offering a glimmer of hope in the fight against pancreatic cancer.
The community's role in the fight against cancer cannot be overstated. The Dolphins Cancer Challenge, now in its 16th year, has raised over $100 million for Sylvester, a testament to the power of community investment. This annual event brings together survivors, supporters, and leaders, united in their commitment to accelerating cancer research and improving patient care. The funds raised directly support breakthrough research, innovative technologies, and personalized treatments, highlighting the impact of community engagement in the battle against cancer.
Sylvester's community outreach initiatives, such as the Game Changer vehicle, take cancer screening and education directly to South Floridians. This mobile approach ensures that preventive care, including free screenings, education, and counseling, reaches those who may not have easy access to traditional healthcare settings. Dr. Erin Kobetz, the driving force behind these initiatives, emphasizes the importance of reducing the cancer burden through proactive and inclusive community engagement.
